Merger Vision advised founders on selling 100% share in NEOX s.r.o., one of the largest independent central European contract research organizations, to a US-based strategic partner. The sale process was organized entirely online.

Founded in 2004, NEOX has provided clinical research support for more than 1,000 studies and has built deep experience across multiple therapeutic areas. Based in Prague, the company operates primarily in central and eastern Europe, with a direct presence in the Czech Republic, Bulgaria, Germany, Hungary, Poland, Romania, Slovakia, and Slovenia.  While in the sale process, NEOX opened an additional branch in the United Kingdom.

Emmes, founded in 1977, is a U.S. full-service clinical research organization (CRO). The company’s clients include numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical, and medical device companies worldwide. The acquisition will establish a direct presence in Europe for Emmes and expand its customer base and capabilities to conduct global trials at sites across the US, Canada, UK, EU, and India.

The sales process occurred during a time of strong anti-Covid measures, including limited travel between the USA and Europe. Thus, for the first time in its history, Merger Vision organized the entire process exclusively online. Through a virtual dataroom, we managed due diligence in eight jurisdictions, while the buyer’s advisory teams worked from their headquarters in the USA, London, and Prague. All management presentations and negotiation of contractual documentation also took place exclusively online.

Please see our transactions for more details and a testimonial from our clients.